SOUTH SAN FRANCISCO, Calif.,
Oct. 25, 2021 /PRNewswire/
-- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the
"Company") today announced that it has received funding from the
Bill & Melinda Gates Foundation to support the demonstration of
its ability to deliver a human immunodeficiency virus ("HIV")
preventative therapeutic and a contraceptive from a single implant
using its proprietary ProNeura® technology, and ensure
this technology is accessible to women and adolescent girls in low-
and middle-income countries.
"Reducing the burden of HIV, while simultaneously increasing
access to contraceptive options, could have a major impact on the
health of women and adolescent girls in low- and middle-income
countries," said Marc Rubin, M.D.,
Executive Chairman of Titan. "We believe that our ProNeura platform
is uniquely suited to this program, as we have demonstrated the
feasibility of long-term delivery of two pharmaceutically active
ingredients from a single implant in an earlier development
program. The continuous long-term delivery of a
contraceptive/antiviral combination has the potential to have a
greater public health impact in developing nations, compared with
daily dosing of multiple compounds."
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is a development
stage company developing proprietary therapeutics with its
ProNeura® long-term, continuous drug delivery
technology. The ProNeura technology has the potential to be used in
developing products for treating a number of chronic conditions,
where maintaining consistent, around-the-clock blood levels of
medication may benefit the patient and improve medical outcomes.
For more information about Titan, please
visit www.titanpharm.com.
Forward-Looking Statements
This press release may contain "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Such statements
include, but are not limited to, any statements relating to our
product development programs and any other statements that are not
historical facts. Such statements involve risks and uncertainties
that could negatively affect our business, operating results,
financial condition and stock price. Factors that could cause
actual results to differ materially from management's current
expectations include those risks and uncertainties relating to our
ability to raise capital, the regulatory approval process, the
development, testing, production and marketing of our drug
candidates, patent and intellectual property matters and strategic
agreements and relationships. We expressly disclaim any obligation
or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in our expectations or any changes in events, conditions or
circumstances on which any such statement is based, except as
required by law.
CONTACT:
Stephen Kilmer
Investor Relations
(650) 989-2215
skilmer@titanpharm.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/titan-pharmaceuticals-receives-funding-to-develop-combination-hiv-therapeutic-and-contraceptive-implant-for-women-in-developing-countries-301407256.html
SOURCE Titan Pharmaceuticals, Inc.